Targeted & controlled bone healing
24 Sep 19
Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North American Spine Society 34 th Annual Meeting

Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North American Spine Society 34th Annual Meeting

  • Kuros to fully launch MagnetOs™ at the North American Spine Society 34th Annual Meeting in Chicago, USA, September 25-28, building on the momentum gained during the initial phased launch.
  • Kuros launches MagnetOs™ website, www.magnetosbonegraft.com.
  • Professor WR Walsh will present pre-clinical data featuring MagnetOs™ in a podium session.

Schlieren (Zurich), Switzerland, September 24, 2019 – Kuros Biosciences, a leader in next generation bone graft technologies, today announces the full commercial launch of MagnetOs™ and the company’s first attendance as an exhibitor at NASS, the world’s largest spine meeting and exhibition. During the meeting, the commercial team will be actively promoting MagnetOs™ to surgeons and hospitals, recruiting new sales staff, agents and distributors to expand the Company’s market reach.

 

Joost de Bruijn, Chief Executive Officer of Kuros, said: “This world-class spine specialty meeting represents a timely opportunity for us to showcase our unique MagnetOs™ technology and to further expand our commercial footprint. We have been delighted with the traction gained during the phased launch of MagnetOs™ and we are ready to deliver its advantages to surgeons across the globe.”

 

Kuros also announces today the launch of its new website to promote MagnetOs™, www.magnetosbonegraft.com.

 

The meeting will also provide an opportunity for Kuros to deliver a podium presentation featuring MagnetOs™. Professor WR Walsh (Surgical & Orthopaedic Research Laboratories (SORL),  University of New South Wales, Australia), will present “Evaluation of three commercially available synthetic bone grafts in a clinically relevant Ovine model of instrumented lumbar fusion” on the morning of Wednesday, September 25 in the Skyline Ballroom (W375d) at the exhibit venue. The evaluation concluded that calcium phosphate with submicron topography (MagnetOs™ Putty) was the only synthetic bone graft to perform equally well as autograft as a stand-alone graft in a posterior lumbar fusion model, and was significantly superior to current market leading synthetic bone grafts.

 

In addition to presenting MagnetOs™, the Kuros team will be introducing the Fibrin-PTH (KUR-113) technology to the spine world, which was recently the subject of an IND application approval by the FDA.



Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Analysts
  5. Calendar
  6. Corporate governance
  7. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Article
24 Sep 19
Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North American Spine Society 34 th Annual Meeting

Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North American Spine Society 34th Annual Meeting

  • Kuros to fully launch MagnetOs™ at the North American Spine Society 34th Annual Meeting in Chicago, USA, September 25-28, building on the momentum gained during the initial phased launch.
  • Kuros launches MagnetOs™ website, www.magnetosbonegraft.com.
  • Professor WR Walsh will present pre-clinical data featuring MagnetOs™ in a podium session.

Schlieren (Zurich), Switzerland, September 24, 2019 – Kuros Biosciences, a leader in next generation bone graft technologies, today announces the full commercial launch of MagnetOs™ and the company’s first attendance as an exhibitor at NASS, the world’s largest spine meeting and exhibition. During the meeting, the commercial team will be actively promoting MagnetOs™ to surgeons and hospitals, recruiting new sales staff, agents and distributors to expand the Company’s market reach.

 

Joost de Bruijn, Chief Executive Officer of Kuros, said: “This world-class spine specialty meeting represents a timely opportunity for us to showcase our unique MagnetOs™ technology and to further expand our commercial footprint. We have been delighted with the traction gained during the phased launch of MagnetOs™ and we are ready to deliver its advantages to surgeons across the globe.”

 

Kuros also announces today the launch of its new website to promote MagnetOs™, www.magnetosbonegraft.com.

 

The meeting will also provide an opportunity for Kuros to deliver a podium presentation featuring MagnetOs™. Professor WR Walsh (Surgical & Orthopaedic Research Laboratories (SORL),  University of New South Wales, Australia), will present “Evaluation of three commercially available synthetic bone grafts in a clinically relevant Ovine model of instrumented lumbar fusion” on the morning of Wednesday, September 25 in the Skyline Ballroom (W375d) at the exhibit venue. The evaluation concluded that calcium phosphate with submicron topography (MagnetOs™ Putty) was the only synthetic bone graft to perform equally well as autograft as a stand-alone graft in a posterior lumbar fusion model, and was significantly superior to current market leading synthetic bone grafts.

 

In addition to presenting MagnetOs™, the Kuros team will be introducing the Fibrin-PTH (KUR-113) technology to the spine world, which was recently the subject of an IND application approval by the FDA.